Compare ASTS & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTS | NTRA |
|---|---|---|
| Founded | 2019 | 2003 |
| Country | United States | United States |
| Employees | 578 | N/A |
| Industry | Telecommunications Equipment | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.0B | 28.0B |
| IPO Year | N/A | 2015 |
| Metric | ASTS | NTRA |
|---|---|---|
| Price | $93.84 | $198.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 14 |
| Target Price | $71.27 | ★ $259.07 |
| AVG Volume (30 Days) | ★ 9.5M | 1.1M |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $210,939,000.00 |
| Revenue This Year | $218.44 | $16.65 |
| Revenue Next Year | $237.34 | $19.22 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.22 | $125.38 |
| 52 Week High | $129.89 | $256.36 |
| Indicator | ASTS | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 51.74 | 43.27 |
| Support Level | $65.77 | $194.03 |
| Resistance Level | $104.73 | $251.09 |
| Average True Range (ATR) | 7.83 | 8.19 |
| MACD | 0.76 | 0.27 |
| Stochastic Oscillator | 53.47 | 42.77 |
AST SpaceMobile Inc is currently designing, developing and manufacturing the constellation of BlueBird (BB) satellites and has begun launching its planned space-based Cellular Broadband network distributed through a constellation of low Earth orbit (LEO) satellites. The company is building a cellular broadband network in space to operate directly with standard, unmodified mobile devices, and off-the-shelf mobile phones based on extensive IP and patent portfolio. It has focused on eliminating the connectivity gaps faced by mobile subscribers. The Company's spaceMobile Service is being designed to provide cost-effective, high-speed Cellular Broadband services to end-users who are out of terrestrial cellular coverage using existing mobile devices.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.